9 results match your criteria: "GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital[Affiliation]"
Factors associated with knowledge and safety skills of arthritis patients receiving biologics: A survey of 677 patients.
Joint Bone Spine
March 2017
Rheumatology Department, Saint-Antoine Hospital, AP⿿HP, 75012 Paris, France.
Objective: We aimed to determine patient and rheumatologist factors associated with the safety skills of patients receiving bDMARDs for inflammatory arthritis.
Methods: Data were obtained from a descriptive observational cross-sectional nationwide survey performed in 2011 in France. Community- and hospital-based rheumatologists were selected at random.
Cross-sectional study of self-care safety skills in 677 patients on biodrugs for inflammatory joint disease.
Joint Bone Spine
December 2014
Service de rhumatologie, CHU de Nancy, Hôpitaux de Brabois, allée du Morvan, 54500 Vandoeuvre-lès-Nancy, France; Université de Lorraine, Université Paris Descartes, Apemac, EA4360, 54000 Nancy, France; INSERM, CIC-EC CIE6, 54000 Nancy, France. Electronic address:
Rationale: Biodrugs carry specific risks that patients must be aware of and capable of managing. Until now, few studies have addressed the self-care safety skills of patients taking biodrugs. The primary objective of this study was to describe the self-care safety skills of patients taking biodrugs for chronic inflammatory joint disease.
View Article and Find Full Text PDFUpdating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
J Rheumatol
May 2014
From the Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris, France; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, The Netherlands; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Division of Musculoskeletal Disease, University of Leeds, and the UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, UK; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles, Los Angeles, California, USA; Université de Lorraine, EA 4360 APEMAC, Nancy; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Oslo University Hospital and Lovisenberg Diaconal University College, Oslo, Norway; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen, Heerlen, The
Objective: The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter requires that criteria be met to demonstrate that the outcome instrument meets the criteria for content, face, and construct validity.
Methods: Discussion groups critically reviewed a variety of ways in which case studies of current OMERACT Working Groups complied with the Truth component of the Filter and what issues remained to be resolved.
Updating the OMERACT filter: discrimination and feasibility.
J Rheumatol
May 2014
From the Cardiovascular Research Methods Centre, Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht, The Netherlands; Australian Health Workforce Institute (AHWI), School of Population Health, University of Melbourne, Melbourne, Australia; Division of Musculoskeletal Disease, University of Leeds, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris, France; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles; Los Angeles, California, USA; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris; Université de Lorraine, Université Paris Descartes, Nancy, France; University of Leeds, Section of Musculoskeletal Disease, LIMM Chapel Allerton Hospital, Leeds West Yorkshire; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Rh
The "Discrimination" part of the OMERACT Filter asks whether a measure discriminates between situations that are of interest. "Feasibility" in the OMERACT Filter encompasses the practical considerations of using an instrument, including its ease of use, time to complete, monetary costs, and interpretability of the question(s) included in the instrument. Both the Discrimination and Reliability parts of the filter have been helpful but were agreed on primarily by consensus of OMERACT participants rather than through explicit evidence-based guidelines.
View Article and Find Full Text PDFUpdating the OMERACT filter: implications for patient-reported outcomes.
J Rheumatol
May 2014
From the University of Bristol, Academic Rheumatology Unit, and the University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, and Department of Medical Humanities, VU University Medical Center, Amsterdam, The Netherlands; National Rheumatoid Arthritis Society, Maidenhead, Berkshire, UK; Faculty of Health Sciences, University of Queensland, Royal Brisbane and Women's Hospital, Herston, Brisbane, Australia; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Université de Lorraine, Université Paris Descartes, Paris, France; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen, Amsterdam, The Netherlands; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Cochrane Musculoskeletal Group, Institute of Population Health, Ottawa, Ontario, Canada; Department of Rheumatology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Consumer Advisory Board, Arthritis Research Centre of Canada, Richmond, British Columbia, Canada; UCB Pharma S.A., Brussels, Belgium; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France.
Objective: At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the "Truth" statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.
View Article and Find Full Text PDFHow to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
J Rheumatol
May 2014
From the Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands; University of Bristol, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS), Paris, France; APHP, Hôpital Pitié-Salpêtrière, Rhumatologie; University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Department of Rheumatology, APHP, Ambroise Paré Hospital, UPRES EA 2506 Université Versailles-Saint Quentin En Yvelines, Boulogne-Billancourt, France; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Australian Health Workforce Institute, School of Population Health, University of Melbourne, Melbourne, Australia; Academic Medical Center University of Amsterdam and Atrium Medical Center Heerlen, Heerlen, The Netherlands; Institute of Bone and Joint Research and Sydney Medical School and School of Public Health, University of Sydney, and Department of Rheumatology, Royal North Shore, St. Leonards, NSW, Australia; SDG LLC, Cambridge, Massachusetts; University of Alabama at Birmingham; Veterans Affairs Medical Center, Birmingham, Alabama; Mayo Clinic College of Medicine, Rochester, Minnesota; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Department of Epidemiology and Community Medicine, and Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Objective: The Outcome Measures in Rheumatology (OMERACT) initiative works to develop core sets of outcome measures for trials and observational studies in rheumatology. At the OMERACT 11 meeting, substantial time was devoted to discussing a conceptual framework and a proposal for a more explicit working process to develop what we now propose to term core outcome measurement sets, collectively termed "OMERACT Filter 2.0.
View Article and Find Full Text PDFDeveloping core outcome measurement sets for clinical trials: OMERACT filter 2.0.
J Clin Epidemiol
July 2014
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Background: Lack of standardization of outcome measures limits the usefulness of clinical trial evidence to inform health care decisions. This can be addressed by agreeing on a minimum core set of outcome measures per health condition, containing measures relevant to patients and decision makers. Since 1992, the Outcome Measures in Rheumatology (OMERACT) consensus initiative has successfully developed core sets for many rheumatologic conditions, actively involving patients since 2002.
View Article and Find Full Text PDFSafety of biologics: elaboration and validation of a questionnaire assessing patients' self-care safety skills: the BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section.
Joint Bone Spine
October 2013
Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, 83, boulevard de l'hôpital, 75013 Paris, France. Electronic address:
Background: Biologics are known to entail specific risks (e.g. infections).
View Article and Find Full Text PDFCost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.
Pharmacoeconomics
December 2012
Universit Pierre et Marie Curie Paris VI, GRC-UMPC 08 (EEMOIS), Paris, France.
Objectives: This report reviews the cost effectiveness of different therapeutic interventions used in the treatment of ankylosing spondylitis (AS).
Methods: We performed a systematic search of the databases MEDLINE via PubMed, EMBASE and the Cochrane Library and used hand-searching to identify articles on cost effectiveness of therapies for adult patients with AS published up to November 2010.
Results: Of 135 articles, 13 studies were analysed.